The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization by Amanda M. Leisgang Osse, Jefferson W. Kinney, Jeffrey L. Cummings

Get full text

Biomarker identification for Alzheimer’s disease through integration of comprehensive Mendelian randomization and proteomics data by Hui Zhan, Davis Cammann, Jeffrey L. Cummings, Xianjun Dong, Jingchun Chen

Get full text

Alzheimer's disease drug development pipeline: 2025 by Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Amanda M. Leisgang‐Osse, Feixiong Cheng

Get full text

Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease by Clive Ballard, Alireza Atri, Neli Boneva, Jeffrey L. Cummings, Lutz Frölich, José Luis Molinuevo, Pierre N. Tariot, Lars Lau Raket

Get full text

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat... by Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens

Get full text

How do we put meaning into meaningful benefit? Perspectives from the lived experience by Russ Paulsen, Carla (DeMuro) Romano, Terry Frangiosa, Margaret Mordin, Gabrielle J. Dardis, Dana DiBenedetti, Ronald C. Petersen, Jeffrey L. Cummings

Get full text